Gamida Cell’s Bone Marrow Transplant Alternative Succeeds In Phase III

 
• By Mandy Jackson

The Novartis-backed company will begin a rolling submission to the US FDA for its cord blood-derived cell therapy omidubicel in Q4 based on improved engraftment versus standard cord blood. 

Young adult woman walking up the stairs with sun sport background.
Gamida Cell's omidubicel is on the path to US FDA submission • Source: Shutterstock

More from Clinical Trials

More from R&D